📘 New publication!

CARB-X Alliance Director Ed Buurman, PhD, MBA, contributed to this article on the current state of #phage therapy , including major R&D challenges and new opportunities for #phage technology based on #AI & synthetic phage production.

🔗 bit.ly/3xpFYbt

📘 New publication!

CARB-X Chief of R&D Erin Duffy, PhD, and Alliance Director Ed Buurman, PhD, MBA, helped develop a Vaccine Value Profile for K. pneumoniae, a major cause of pneumonia, bloodstream infections, & infections in newborns.

🔗 Read more: bit.ly/3IVVs9S

Join CARB-X’s Chief Scientific Officer Richard Alm, PhD, at the World Vaccine Congress in Washington D.C., on April 1, 2024. During his talk, he will discuss Accelerating the Development of Novel Tools against AMR.

#WorldVaccineCongress #AMR

Join CARB-X’s Chief Scientific Officer Richard Alm, PhD, at the World Vaccine Congress in Washington D.C., on April 1, 2024. During his talk, he will discuss Accelerating the Development of Novel Tools against AMR.

#WorldVaccineCongress #AMR

⏰ Expressions of Interest are due tomorrow!

Submit Expressions of Interest for #preventatives , #therapies , & #diagnostics for drug-resistant bacteria by tomorrow, Mar. 29 at 23:59 ET to be considered in the first of two application cycles.

🔗 Apply: bit.ly/3P56UDB

⏰ Deadline approaching! Expressions of Interest due in 1 WEEK.

Submit Expressions of Interest for #preventatives , #therapies , & #diagnostics for drug-resistant bacteria by Mar 29 at 23:59 ET to be considered in the 1st of 2 application cycles.

🔗 Apply: bit.ly/3P56UDB

🌐 WEBINAR: Sign up to learn about the scope & application process for this year’s funding round for #preventatives , #therapies , & #diagnostics for drug-resistant bacteria.

Plus, pose questions to the CARB-X team.

21 March 19:00 ET
22 March 08:00 ET

🔗 bit.ly/3P56UDB

📢 ADVANCE-ID Network is announcing a new #funding opportunity for Phase II or III clinical trials of novel antimicrobial agents for the treatment or prevention of infections due to multi-resistant Gram negative bacilli.

🗓️ Deadline to apply: March 15

bit.ly/49aHbBs

Join the AMR COMBINE webinar on developing target product profiles for antibiotics! Dr. Erin Duffy CARB-X will cover “How CARB-X Expects a TPP to Be Included in Funding Applications.”

🗓 Friday, March 15
⏰ 2:35 PM CET
🔗 bit.ly/3V4NFha

📢 ADVANCE-ID Network is announcing a new #funding opportunity for Phase II or III clinical trials of novel antimicrobial agents for the treatment or prevention of infections due to multi-resistant Gram negative bacilli.

🗓️ Deadline to apply: March 15

bit.ly/49aHbBs

Join the AMR COMBINE webinar on developing target product profiles for antibiotics! Dr. Erin Duffy CARB-X will cover “How CARB-X Expects a TPP to Be Included in Funding Applications.”

🗓 Friday, March 15
⏰ 2:35 PM CET
🔗 bit.ly/3V4NFha

Join the AMR COMBINE webinar on developing target product profiles for antibiotics! Dr. Erin Duffy CARB-X will cover “How CARB-X Expects a TPP to Be Included in Funding Applications.”

🗓 Friday, March 15
⏰ 2:35 PM CET
🔗 bit.ly/3V4NFha

Join the AMR COMBINE webinar on developing target product profiles for antibiotics! Dr. Erin Duffy CARB-X will cover “How CARB-X Expects a TPP to Be Included in Funding Applications.”

🗓 Friday, March 15
⏰ 2:35 PM CET
🔗 bit.ly/3V4NFha